Retraining macrophages to kill tumors
Some tumors avoid getting killed by turning macrophages into immune-suppressive cells. Hagemann et al. (page 1261) now find that these impotent cells can be reverted into weapons of tumor destruction by simply suppressing a kinase.
Macrophages can destroy tumor cells by producing inflammatory molecules. But macrophages within tumors often secrete harmless antiinflammatory cytokines and proteins that promote tumor growth. Tumor cells induce this transformation, but the signals that drive the conversion were unknown.
Hagemann et al. now find that tumor macrophages in mice are disarmed by signals that activate NF-κB-a transcription factor that normally drives inflammation. As in inflammation, tumor macrophage NF-κB was turned on by IκB kinase (IKK) β. In tumors, however, IKKβ also suppressed STAT1-a transcription factor that turns on tumor-fighting genes. The basis for this difference is unclear. Perhaps the tumor contains unique cues that instruct the IKK pathway to shut off STAT1.
STAT1 suppression in macrophages depended solely on the cytokine receptor IL-1R and its downstream adaptor, MyD88, suggesting that tumors might protect themselves by secreting the IL-1R ligand, IL-1β. Macrophages from tumors or from healthy animals became in vivo tumor killers when engineered to express dominant-negative IKKβ. These reprogrammed macrophages produced high levels of IL-12, which recruited tumor-fighting NK cells. The group is now investigating whether infusing similarly reprogramed macrophages into cancer patients will help reverse tumor growth.
Endothelial cells instigate sepsis
During severe bacterial infections, the transcription factor NF-κB is both an asset and a liability. On page 1303, Ye et al. show that its activation in endothelial cells singlehandedly perpetuates the inflammation that drives septic shock.
NF-κB is required in endothelial cells for new blood vessels to grow. And in immune cells, its activation is essential for defense against bacteria and other infectious agents. Blocking NF-κB in mice, for example, turns a normally manageable infection deadly. But more selectively inactivating the protein has proven beneficial in other systems, including certain cancer models.
Following this lead, Ye et al. disabled NF-κB activation only in endothelial cells. The resulting mice survived a normally lethal bacterial infection and avoided septic shock. Being free of active NF-κB allowed the endothelial cells lining blood vessels to maintain their cell-cell junctions and minimize their stickiness, thus limiting the fluid leakage and massive immune cell infiltration into tissues that triggers shock.
Thus, NF-κB-driven activation of endothelial cells, not immune cells, seems to be the driving force behind the escalating inflammation that causes sepsis. 
